Journals / Kocatepe Veteriner Dergisi / 2015 / Cilt: 8 - Sayı: 1

Oral Antidiabetic Drugs

Oral Antidiyabetik İlaçlar

Pages
95–102
Publication Date
2015-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In recent years, many new drugs developed for the treatment of diabetes, passing combination therapy achieved important goals.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetes mellitus is a chronic hyperglycemia metabolism disorder that leads to carbohydrate, protein, and fat metabolism disorders as a result of the effect of absolute or relative lack of insulin hormone secretion or insulin.
📊
Key Findings & Data:The treatment of diabetes, in 20 beginning of the century while the discovery of insulin was a turning point, the increase of information on the pathogenesis of the disease and advances in technology and the provision of control and tried to reach the targets for the prevention of complications.
💡
Conclusion & Impact:In recent years, many new drugs developed for the treatment of diabetes, passing combination therapy achieved important goals.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Diabetes mellitus · İlaç · Tedavi.

Abstract

Diabetes mellitus is a chronic hyperglycemia metabolism disorder that leads to carbohydrate, protein, and fat metabolism disorders as a result of the effect of absolute or relative lack of insulin hormone secretion or insulin. Social point of view, due to the acute and chronic complications that can lead to disability and death, which reduces the quality of life and social-economic burden of a disease, is noteworthy. Patients with diabetes are forced to sustain a scheduled care throughout their life and get help from time to time. The treatment of diabetes, in 20 beginning of the century while the discovery of insulin was a turning point, the increase of information on the pathogenesis of the disease and advances in technology and the provision of control and tried to reach the targets for the prevention of complications. Antidiabetic drugs used to provide glucose control, but it is known to be limited in effect to stop the progression of the disease. In recent years, many new drugs developed for the treatment of diabetes, passing combination therapy achieved important goals.

Özet

Diabetes mellitus insülin hormon sekresyonunun veya insülin etkisinin mutlak veya göreceli azlığı sonucu karbonhidrat, protein ve yağ metabolizmasında bozukluklara yol açan kronik hiperglisemik bir grup metabolizma hastalığıdır. Diyabet akut ve kronik komplikasyonlar nedeniyle sakatlık ve ölümlere yol açabilen ve yaşam kalitesini düşüren ve sosyo-ekonomik yük getiren bir hastalık olarak dikkat çekmektedir. Diyabetli hasta yaşam boyunca planlanmış bir bakımı sürdürmek ve zaman zaman yardım almak zorundadır. Diyabet tedavisinde, 20. yüzyılın başları insülinin keşfedilmesi ile bir dönüm noktası olurken, hastalığın patogenezi ile ilgili bilgilerin artması ve teknolojideki gelişmeler ile iyi metabolik kontrolün sağlanmasına ve komplikasyonların önlenmesine yönelik hedeflere ulaşılmaya çalışılmıştır. Kullanılan antidiyabetik ilaçların glukoz kontrolünü sağladığı, fakat hastalığın ilerlemesini durdurma konusunda etkilerinin sınırlı olduğu bilinmektedir. Son yıllarda birçok yeni ilaç geliştirilmiştir ve birçok ilacın birlikte kullanılması ile kombinasyon tedavilerine geçilerek önemli hedeflere ulaşılmıştır.

🔖

Cite This Article

ÇUBUK, G., İNCE, S. (2015). Oral Antidiabetic Drugs. Kocatepe Veteriner Dergisi, Cilt: 8 - Sayı: 1, 95–102. https://ajindex.com/articles/124700

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Akçay G. Diabetes mellitus’un tanı ve tedavisindeki gelişmeler. İç Hastalıkları Mezuniyet Sonrası Eğitim Kursu. Atatürk Üniversitesi Tıp Fakültesi, Erzurum, 2001.
  2. Aktunç E, Ünalacak M, Demircan N. Tip II Diyabet’te Patofizyoloji ve Akılcı Tedavi Yaklaşımı STED, 2002; 11 (9): 334–336.
  3. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007; 298: 194-206. Anonim. http://www.eczanet.com/; Erişim tarihi: 24.12.2012.
  4. Ayvaz G, Kan E. Tip 2 Diabetes Mellitus Tedavisinde Oral Antidiyabetik Ajanlar. Mised, 2010; 23-24: 8-13.
  5. Bailey CJ, Day C. Thiazolidinediones today. Brit J Diab Vasc Dis. 2001; 1: 7-13.
  6. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. 13. Harrison İç Hastalıkları Prensipleri, Cilt 2, Nobel Kitabevleri, 2004; s: 2109-2138.
  7. Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications. 2000; 14: 201-6.
  8. Brunner LS, Suddarth DS. Textbook of Medical Surgical Nursing, 10th edition, Tahran, 2004; pp: 261-267. 102 Chiasson JL, Josse RG, Hunt JA. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann. Intern. Med. 1994; 121: 928-35.
  9. Crandall JP, Knowler WC. Diabetes Prevention Program Research Group. The prevention of type 2 diabetes. Nat. Clin. Pract. Endocrinol. Metab. 2008; 4: 382-393. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med. 1999; 16: 179-192.
  10. Derosa G, Mugellini A, Ciccarelli L. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin. Ther. 2003; 25: 472-84.
  11. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J. Clin. Endocrinol. Metab. 2002; 87: 1282-90. Erdogan G. Kologlu-Endokrinoloji Temel ve Klinik MN Medikal ve Nobel Yayınevi 2. Baskı, 2005; s: 245-97.
  12. Fürnsinn C, Waldhusl W. Thiazolidindiones: Metabolic Actions in Vitro, Diabetologia. 2002; 45: 1211-23.
  13. Gilmer TP, Oconnor PJ, Manning WG, Rush WA. The costto health plans of poor glycemic control. Diabetes Care. 1997; 20: 1847-53.
  14. Goldstein, B.J. Differentiating members of the thiazolidindione class: a focus on efficacy. Diabetes Metab. Res. Rev. 2002; 18: 16-22. Gren B. Gliptins: